Novonesis A/s Class B · OMXCOP:NSIS_B

Novonesis A/s Class B — Novozymes — FY2013 Earnings Presentation

10 slides from Novonesis A/s Class B's earnings presentation, Jan 21, 2014

  1. Slide 1: Conference Call Full Year 2013

    CONFERENCE CALL FULL YEAR 2013 January 21, 2014

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation and its related comments contain forward- looking statements, including financial expectations. Forward-looking statements are by their very nature associated with risks and uncertainties that may cause actual results to differ materially from expectations. Th

  3. Slide 3: Full-Year 2013 Summary

    Full-Year 2013 Summary 2013 performance as expected 2011-2013 DKKm sales and org. growth • 7% organic sales growth (5% in DKK) driven by all 12% 12.000 industries, primarily Household Care and Bioenergy 10% 11.746 8% 11.000 • Good Q4 with 8% organic sales growth 7% 11.234 6% 7% 10.510 • EBIT margin

  4. Slide 4: Sales & Markets

    Sales & Markets  FY 2013 sales: DKK +5%, LCY +8%, org. +7% Sales by industry, DKKm  Q4 2013 sales: DKK +5%, LCY +9%, org. +8% 2013 2012 • Household Care: Sales continued on growth track, Household 4.222 +6%/+9% as strong performance in emerging markets and Care Q4: +13% 3.973 Europe/MEA made up fo

  5. Slide 5: The BioAg Alliance with Monsanto

    The BioAg Alliance with Monsanto - Aiming to build next important yield platform for farmers INTEGRATED SYSTEM EMERGING TRENDS • Multiple components converging to • Replacing agricultural inputs with drive yield and productivity with sustainable, cost-effective solutions more platforms coming togeth

  6. Slide 6: 2013 – A Year of Significant Innovation

    2013 – A Year of Significant Innovation The BioAg Alliance 11 products launched in 2013 • Combination of Novozymes and Monsanto establishes • Significant innovation brought industry's most advanced microbials platform to Bioenergy and Household • Vast opportunites in combining capabilities and explo

  7. Slide 7: Manufacturing Performance

    Manufacturing Performance Satisfactory gross margin on par with 2012 Gross margin development, 2000-2013 58% 57,2% • Acquisitions and currencies had a negative 56,2% impact 56% 55,6% 57,2% • Great performance on strain optimization 55,7% 54% 53,3% and protein engineering 52,4% 53,1% 51,8% 53,7% 53,5

  8. Slide 8: Sustainability Performance and Targets

    Sustainability Performance and Targets 2013 sustainability performance: good progress, but not all targets met 2013 2013 Targets target realized 2014 target Water efficiency (index 2005) 35% 33% 34% Energy efficiency (index 2005) 42% 40% 42% CO2 efficiency (index 2005) 50% 54% >50% Million tons CO2

  9. Slide 9: 2013 Financial Performance & 2014 Outlook

    2013 Financial Performance & 2014 Outlook Satisfactory results for 2013 Realized Outlook for • Sales growth picked up from 2012 Key financials 2013 2014 • Record-high EBIT margin despite negative effects Sales growth, DKK +5% 4-7% from currency and acquisitions • Proposed dividend: Sales growth, LCY

  10. Slide 10: Novozymes – Rethink Tomorrow

    novozymes’ Rethink Tomorrow

Novozymes — FY2013 Earnings Presentation on 6ix